Genomic profiling in this study has thus confirmed the previous finding of frequent aberration in the CDK4 pathway of acral melanoma subjects [29] and suggested a combination potential of CDK4/6 inhibitor, FGF/FGFR inhibitor, or DNA repair targeting agent such as PARP inhibitor with PD-1 blockade in treating acral melanomas. The gene discussed is CDK4; the disease is acral lentiginous melanoma.